The European Association for the Study of the Liver Congress 2026 (EASL Congress 2026) will take place from May 27 to 30 in Barcelona, Spain. Organized by the European Association for the Study of the Liver, EASL Congress is one of the largest and most academically prestigious annual events in the field of hepatology, bringing together thousands of liver researchers, clinicians, and industry experts from around the world. The results from a phase 2 study of DR10624, a long-acting FGF21R/GCGR/GLP-1R trispecific agonist independently developed by Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics"), a subsidiary of Huadong Medicine Co., Ltd., on liver fat and hepatic metabolic markers in patients with severe hypertriglyceridemia will be presented globally as a poster at the congress.
EASL 2026 Congress Presentation Information
-
Title: DR10624, a novel FGF21R/GCGR/GLP-1R triple agonist, significantly reduced liver fat and improved hepatic and metabolic biomarkers in a phase 2 study of patients with severe hypertriglyceridemia
-
Presentation Format: Poster
-
Abstract Number: FRI-156
-
Presentation Date and Time: Friday, May 29, 2026, 8:30–17:00 (CEST)
About DR10624
DR10624 is an innovative fusion protein developed based on Doer Biologics' proprietary MultipleBody® technology platform. The molecule fuses an FGF21 analog with a GCG/GLP-1 dual-action hybrid peptide to the Fc fragment of a human IgG1 antibody, enabling simultaneous activation of the fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon-like peptide-1 receptor (GLP-1R). This achieves multi-dimensional synergistic intervention in glucose and lipid metabolism, energy balance, and hepatic fat deposition. DR10624 received clinical trial approval in New Zealand in April 2022 and in China in July 2023. Currently, in addition to the completed phase 2 study in severe hypertriglyceridemia (SHTG), multiple phase 2 studies in MASLD and DKD are also being advanced.
The multiple benefits of DR10624 in hepatic fat deposition and systemic metabolic regulation have led to its designation as a Breakthrough Therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and the first phase 3 study (for SHTG indication) has been initiated. This product has the potential to provide a more comprehensive and effective treatment option for patients with severe hypertriglyceridemia (SHTG), mixed hyperlipidemia, and metabolic dysfunction-associated steatohepatitis (MASH). Doer Biologics will continue to advance the clinical development of DR10624, striving to provide patients with more effective and comprehensive treatment choices.
The presentation of these DR10624 research results at EASL 2026 marks a further enhancement of the international academic influence of this innovative pipeline in the field of liver and metabolic diseases and reflects Doer Biologics' continued innovation capabilities in the research and development of new drugs for complex metabolic diseases.